Panel: Small benefit with Lilly's NSCLC drug; relevance short?
This article was originally published in Scrip
Executive Summary
For the most part, the members of the FDA's Oncologic Drugs Advisory Committee (ODAC) on 9 July said the risk-benefit ratio favors Lilly's necitumumab as a treatment for patients with squamous non-small-cell lung cancer (NSCLC) – a disease with a particularly poor prognosis.